Publications by authors named "Zheng-Hui Ye"
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high risk of invasion and metastasis along with a poor prognosis.
Aim: To investigate the independent predictive markers for disease-free survival (DFS) in patients with HCC and establish a trustworthy nomogram.
Methods: In this study, 445 patients who were hospitalized in The First Affiliated Hospital of Anhui Medical College between December 2009 and December 2014 were retrospectively examined.
Background: Acute-on-chronic liver failure (ACLF) patients have high mortality in a short period of time. This study aimed to compare the prognosis of transplanted ACLF patients to that of nontransplanted ACLF patients and decompensated cirrhosis recipients.
Methods: Clinical data of 29 transplanted ACLF patients, 312 nontransplanted ACLF patients, and 60 transplanted decompensated cirrhosis patients were retrospectively collected.
Article Synopsis
- Immune checkpoint inhibitors, like toripalimab, are becoming popular in treating solid tumors, including liver cancer (HCC).
- The safety of these inhibitors before or after liver transplant is still unclear, with previous reports mainly focusing on posttransplant rejection issues.
- In a case study, a patient who received toripalimab before liver transplant experienced severe acute hepatic necrosis, suggesting a potential link to immune rejection triggered by the treatment.